

Alexander R Lyon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1449937/publications.pdf>

Version: 2024-02-01

144
papers

20,068
citations

20817

60
h-index

11939

134
g-index

145
all docs

145
docs citations

145
times ranked

19613
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. <i>Cardiovascular Research</i> , 2022, 118, 1758-1770.	3.8	30
2	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
3	Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. <i>European Journal of Heart Failure</i> , 2022, 24, 274-286.	7.1	34
4	The year in cardiovascular medicine 2021: cardio-oncology. <i>European Heart Journal</i> , 2022, , .	2.2	6
5	Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 1: overview and the central role for catecholamines and sympathetic nervous system. <i>European Journal of Heart Failure</i> , 2022, 24, 257-273.	7.1	36
6	Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?. <i>JACC: CardioOncology</i> , 2022, 4, 113-123.	4.0	23
7	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.2	14
8	An integrated approach to cardioprotection in lymphomas. <i>Lancet Haematology</i> , the, 2022, 9, e445-e454.	4.6	5
9	Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. <i>Heart</i> , 2021, 107, 1327-1335.	2.9	23
10	Cardiovascular changes during peanut-induced allergic reactions in human subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 633-642.	2.9	37
11	CMR unveiling the cause of post CoVid-19 infection chest pain. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2025-2026.	1.5	2
12	Pathophysiology of Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 77, 902-921.	2.8	125
13	Cardio-oncology: rationale, aims and future directions. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 134-140.	1.3	6
14	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.1	37
15	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	4.0	80
16	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
17	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	2.8	97
18	Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 149-163.	2.5	35

#	ARTICLE	IF	CITATIONS
19	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 854-871.	7.1	105
20	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. <i>Journal of Cardiac Failure</i> , 2021, 27, 727-743.	1.7	29
21	Cardio-oncology for the general cardiologist. <i>Heart</i> , 2021, 107, 1254-1266.	2.9	6
22	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€”Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 947-959.	1.0	37
23	What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. <i>Clinical Oncology</i> , 2021, 33, 483-493.	1.4	5
24	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. <i>Circulation: Heart Failure</i> , 2021, 14, e008209.	3.9	24
25	Short- and Long-Term Clinical Outcomes for Patients With Takotsubo Syndrome and Patients With Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017290.	3.7	24
26	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 611-621.	1.8	33
27	Ventricular arrhythmias in patients with immune checkpoint inhibitor myocarditis. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
28	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€”glucose coâ€”transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
29	Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. <i>Current Heart Failure Reports</i> , 2020, 17, 397-408.	3.3	12
30	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€”Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€”Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	7.1	184
31	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	3.8	51
32	Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device â€” the SERCA-LVAD TRIAL. <i>Gene Therapy</i> , 2020, 27, 579-590.	4.5	35
33	The Role of Biomarkers in Cardio-Oncology. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 431-450.	2.4	92
34	Device closure for patent foramen ovale in patients with cryptogenic stroke: which patients should get it?. <i>European Heart Journal Supplements</i> , 2020, 22, M43-M50.	0.1	3
35	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> . 2020. 22. 2272-2289.	7.1	92
36	Cancer and cardiovascular disease â€” Authors' reply. <i>Lancet, The</i> , 2020, 395, 1904-1905.	13.7	0

#	ARTICLE	IF	CITATIONS
37	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	329.8	29
38	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020,	7.1	364
39	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
40	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
41	Baseline cardiovascular risk assessment in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (<HFA>), the European Association of Cardiovascular Imaging (<EACVI>) and the Cardio-Oncology Council of the European Society of Cardiology (<ESC>). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	7.1	234
42	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2020, 317, 167-173.	1.7	25
43	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	2.2	212
44	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
45	Pazopanib and Foscarnet in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	1.4	14
46	Takotsubo syndrome in Heart Failure and World Congress on Acute Heart Failure 2019: highlights from the experts. <i>ESC Heart Failure</i> , 2020, 7, 400-406.	3.1	13
47	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	2.8	179
48	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020, 41, 1720-1729.	2.2	154
49	The year in cardiology 2019: heart failure. <i>Revista Romana De Cardiologie</i> , 2020, 30, 185-204.	0.1	0
50	Cardio-Oncology Services: rationale, organization, and implementation. <i>European Heart Journal</i> , 2019, 40, 1756-1763.	2.2	195
51	Heart failure resulting from cancer treatment: still serious but an opportunity for prevention. <i>Heart</i> , 2019, 105, 6-8.	2.9	16
52	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
53	Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. <i>Lancet</i> , 2019, 394, 1041-1054.	13.7	294
54	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. <i>Heart Failure Reviews</i> , 2019, 24, 915-925.	3.9	39

#	ARTICLE	IF	CITATIONS
55	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
56	Break a sweat to reduce cardiotoxicity – the benefits of exercise training during anthracycline chemotherapy. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 301-304.	1.8	2
57	Cardiovascular disease following breast cancer treatment: can we predict who will be affected?. <i>European Heart Journal</i> , 2019, 40, 3921-3923.	2.2	9
58	Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 68-79.	4.0	66
59	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	7.1	182
60	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
61	Is P2Y12 inhibitor therapy associated with an increased risk of cancer?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 100-104.	3.0	7
62	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
63	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.9	42
64	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	7.1	224
65	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
66	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
67	Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. <i>Current Oncology Reports</i> , 2019, 21, 45.	4.0	20
68	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
69	Late onset heart failure after childhood chemotherapy. <i>European Heart Journal</i> , 2019, 40, 798-800.	2.2	18
70	Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous takotsubo syndrome – insights from exercise echocardiography. , 2019, , .		0
71	P1497 Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous Takotsubo syndrome - Insights from exercise echocardiography. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
72	Recent advances in cardio-oncology: a report from the Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019™. <i>ESC Heart Failure</i> , 2019, 6, 1140-1148.	3.1	34

#	ARTICLE	IF	CITATIONS
73	Cardiovascular events in cancer survivors. <i>Seminars in Oncology</i> , 2019, 46, 426-432.	2.2	8
74	Monitoring the heart during cancer therapy. <i>European Heart Journal Supplements</i> , 2019, 21, M44-M49.	0.1	14
75	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.2	123
76	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	7.1	138
77	Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in β_2 AR-cAMP Responsiveness in Murine Hearts. <i>Cell Reports</i> , 2018, 23, 459-469.	6.4	51
78	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018, 138, 678-691.	1.6	229
79	Heart failure with preserved ejection fraction. <i>Clinical Medicine</i> , 2018, 18, s24-s29.	1.9	23
80	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239
81	The effect of head-up tilt upon markers of heart rate variability in patients with atrial fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12511.	1.1	5
82	Chronic intake of 4-Methylimidazole induces Hyperinsulinemia and Hypoglycaemia via Pancreatic Beta Cell Hyperplasia and Glucose Dyshomeostasis. <i>Scientific Reports</i> , 2018, 8, 17037.	3.3	9
83	Modern-day cardio-oncology: a report from the "Heart Failure and World Congress on Acute Heart Failure 2018". <i>ESC Heart Failure</i> , 2018, 5, 1083-1091.	3.1	23
84	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
85	Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. <i>BMJ: British Medical Journal</i> , 2018, 363, k3845.	2.3	91
86	Activity and outcomes of a cardio-oncology service in the United Kingdom: a five-year experience. <i>European Journal of Heart Failure</i> , 2018, 20, 1721-1731.	7.1	105
87	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , The, 2018, 19, e447-e458.	10.7	376
88	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018, 2, 1633-1644.	5.2	66
89	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. <i>European Heart Journal</i> , 2018, 39, 2032-2046.	2.2	972
90	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. <i>European Heart Journal</i> , 2018, 39, 2047-2062.	2.2	521

#	ARTICLE	IF	CITATIONS
91	Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 55.	0.9	69
92	Gut microbial degradation of organophosphate insecticides-induces glucose intolerance via gluconeogenesis. Genome Biology, 2017, 18, 8.	8.8	88
93	Proteasome Inhibitors as a Potential Cause of Heart Failure. Heart Failure Clinics, 2017, 13, 289-295.	2.1	19
94	Effects of renal denervation on vascular remodelling in patients with heart failure and preserved ejection fraction: A randomised control trial. JRSM Cardiovascular Disease, 2017, 6, 204800401769098.	0.7	7
95	T-tubule remodelling disturbs localized β 2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure. Cardiovascular Research, 2017, 113, 770-782.	3.8	53
96	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	7.1	17
97	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
98	Takotsubo syndrome: aetiology, presentation and treatment. Heart, 2017, 103, 1461-1469.	2.9	136
99	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	7.1	920
100	Cardiac Atrophy and Heart Failure In Cancer. Cardiac Failure Review, 2017, 03, 62.	3.0	29
101	Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. Cardiovascular Research, 2017, 113, 1743-1752.	3.8	102
102	Cardiotoxicity Following Cancer Treatment. Ulster Medical Journal, 2017, 86, 3-9.	0.2	7
103	A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H465-H475.	3.2	7
104	Renal denervation in heart failure with preserved ejection fraction ($\langle \text{RDT} \hat{=} \text{PEF} \rangle$): a randomized controlled trial. European Journal of Heart Failure, 2016, 18, 703-712.	7.1	62
105	A conducting polymer with enhanced electronic stability applied in cardiac models. Science Advances, 2016, 2, e1601007.	10.3	173
106	Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer, 2016, 16, 912.	2.6	30
107	Stressing the Importance of Cardiac Assessment in Pheochromocytoma $\hat{=}$. Journal of the American College of Cardiology, 2016, 67, 2375-2377.	2.8	11
108	Microdomain-Specific Modulation of L-Type Calcium Channels Leads to Triggered Ventricular Arrhythmia in Heart Failure. Circulation Research, 2016, 119, 944-955.	4.5	101

#	ARTICLE	IF	CITATIONS
109	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 8-27.	7.1	835
110	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	2.2	1,996
111	Challenges of Chronic Cardiac Problems in Survivors of Takotsubo Syndrome. <i>Heart Failure Clinics</i> , 2016, 12, 551-557.	2.1	4
112	Microtubule-Dependent Mitochondria Alignment Regulates Calcium Release in Response to Nanomechanical Stimulus in Heart Myocytes. <i>Cell Reports</i> , 2016, 14, 140-151.	6.4	55
113	The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 90-94.	3.0	15
114	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	13.7	373
115	Cardio-oncology: Concepts and practice. <i>Indian Heart Journal</i> , 2016, 68, S77-S85.	0.5	20
116	Risk of hypertension (HTN) and malignant hypertension (mHTN) in patients treated for multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8049-8049.	1.6	0
117	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β^2 -adrenergic signaling and enhances apoptosis. <i>Cell Death and Disease</i> , 2015, 6, e1754-e1754.	6.3	98
118	Standard and Advanced Echocardiography in Takotsubo (Stress) Cardiomyopathy: Clinical and Prognostic Implications. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 57-74.	2.8	97
119	Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts. <i>Cardiovascular Research</i> , 2015, 105, 31-43.	3.8	23
120	Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials. <i>Hypertension</i> , 2015, 65, 401-406.	2.7	44
121	Microcirculatory dysfunction and autonomic disturbance in Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 497-497.	13.7	1
122	A cross-sectional imaging study to identify organs at risk of thermal injury during renal artery sympathetic denervation. <i>International Journal of Cardiology</i> , 2015, 197, 235-240.	1.7	4
123	The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. <i>Human Gene Therapy</i> , 2015, 26, 293-304.	2.7	33
124	Epidemiology and pathophysiology of Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 387-397.	13.7	283
125	Bubbles in Ballooning: Safety and Utility. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 845.	2.8	1
126	Use of cardiac MRI to diagnose Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 669-669.	13.7	6

#	ARTICLE	IF	CITATIONS
127	Gene therapy for GM1 gangliosidosis: challenges of translational medicine. <i>Annals of Translational Medicine</i> , 2015, 3, S28.	1.7	6
128	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e21516-e21516.	1.6	0
129	Gene Therapy for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2014, 129, 2633-2635.	1.6	7
130	Computational modeling of Takotsubo cardiomyopathy: effect of spatially varying β_2 -adrenergic stimulation in the rat left ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H1487-H1496.	3.2	24
131	Caveolin-3 regulates compartmentation of cardiomyocyte β_2 -adrenergic receptor-mediated cAMP signaling. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 67, 38-48.	1.9	103
132	Diagnostic criteria for takotsubo syndrome: A call for consensus. <i>International Journal of Cardiology</i> , 2014, 176, 274-276.	1.7	41
133	Pathophysiology of Takotsubo Syndrome. <i>Circulation Journal</i> , 2014, 78, 1550-1558.	1.6	36
134	Cardiac contractility modulation therapy in advanced systolic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 584-598.	13.7	67
135	Takotsubo cardiomyopathy. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 96-103.	0.5	2
136	Irreversible apical ballooning may also occur. <i>British Journal of Hospital Medicine (London, England: 2005)</i> Tj ETQq0 0 0 rgBT /Overlqck 10 Tf 5	0.5	0
137	Plasticity of Surface Structures and β_2 -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 357-365.	3.9	102
138	High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a β_2 -Adrenergic Receptor/G-protein-Dependent Manner. <i>Circulation</i> , 2012, 126, 697-706.	1.6	625
139	SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 362-372.	4.8	147
140	Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6854-6859.	7.1	334
141	Cardiac Stem Cell Therapy and Arrhythmogenicity: Prometheus and the arrows of Apollo and Artemis. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 207-216.	2.4	1
142	Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 22-29.	3.3	694
143	Gene therapy: targeting the myocardium. <i>Heart</i> , 2008, 94, 89-99.	2.9	94
144	Authors' response to "Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning". <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, E2-E2.	3.3	6